308 related articles for article (PubMed ID: 9818279)
1. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
[TBL] [Abstract][Full Text] [Related]
2. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
4. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.
Savelli G; Lucignani G; Seregni E; Marchianò A; Serafini G; Aliberti G; Villano C; Maccauro M; Bombardieri E
Nucl Med Commun; 2004 May; 25(5):445-9. PubMed ID: 15100502
[TBL] [Abstract][Full Text] [Related]
6. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
[TBL] [Abstract][Full Text] [Related]
7. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.
Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600
[TBL] [Abstract][Full Text] [Related]
8. The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours.
Jilesen AP; Hoefnagel SJ; Busch OR; Bennink RJ; Gouma DJ; Nieveen van Dijkum EJ
Clin Radiol; 2016 Jun; 71(6):537-42. PubMed ID: 27016111
[TBL] [Abstract][Full Text] [Related]
9. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
10. Localisation of neuroendocrine tumours of the upper gastrointestinal tract.
Zimmer T; Ziegler K; Bäder M; Fett U; Hamm B; Riecken EO; Wiedenmann B
Gut; 1994 Apr; 35(4):471-5. PubMed ID: 8174983
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?
Amthauer H; Ruf J; Böhmig M; Lopez-Hänninen E; Rohlfing T; Wernecke KD; Plöckinger U; Gutberlet M; Lemke AJ; Steinmüller T; Wiedenmann B; Felix R
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):342-8. PubMed ID: 14652697
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
[TBL] [Abstract][Full Text] [Related]
14. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
15. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).
de Herder WW
Eur J Endocrinol; 2014 May; 170(5):R173-83. PubMed ID: 24723670
[TBL] [Abstract][Full Text] [Related]
16. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
17. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.
Gabriel M; Muehllechner P; Decristoforo C; von Guggenberg E; Kendler D; Prommegger R; Profanter C; Moncayo R; Virgolini I
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):237-44. PubMed ID: 16172569
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
20. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen.
Adams S; Baum RP; Hertel A; Schumm-Dräger PM; Usadel KH; Hör G
Nucl Med Commun; 1998 Jul; 19(7):641-7. PubMed ID: 9853344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
